Try our Advanced Search for more refined results
Life Sciences
-
January 20, 2026
Fed. Circ. Revives Inventor's Spinal Patent Case Against DePuy
The Federal Circuit on Tuesday revived an inventor's patent infringement suit against DePuy Synthes Cos., ruling that the persuasiveness of expert testimony that was excluded by a lower court is best left for the jury.
-
January 20, 2026
Philips CPAP Cancer Suit Sent Back To Kentucky
A Pennsylvania federal judge has sent back to state court a suit in the multidistrict litigation over recalled CPAP devices brought against Philips RS North America by a Kentucky woman who claims her sleep apnea machine caused her cancer, finding that a middleman supplier wasn't added to thwart federal jurisdiction.
-
January 20, 2026
NY Judge Orders SD To Pause Action Against Abortion Ads
A New York federal judge has temporarily barred South Dakota officials from taking action against an abortion rights group that launched an advertising campaign in the state promoting its website, which explains how to order abortion medication online.
-
January 20, 2026
Ex-Med Spa Workers Say Poaching Claims Can't Stay In Conn.
Two former Connecticut medical spa workers have asked a judge to dismiss claims they lured clients and a colleague to a nearby competitor, saying their employment agreements select Delaware as the necessary forum and venue for any dispute.
-
January 20, 2026
Johnson & Johnson Faces 2nd Talc Trial In Philadelphia
Counsel for a woman who died of ovarian cancer told a Philadelphia jury Tuesday that her condition was caused by her decades-long use of asbestos-laced talc in Johnson & Johnson's flagship baby powder and that the company kept pushing the product in the market despite knowing about its health risks.
-
January 20, 2026
Va. Lawmakers Eye Psilocybin Regulation Pending FDA Action
Virginia lawmakers have introduced legislation directing state regulators to develop rules governing the prescription, possession and use of medical psilocybin, the active compound in psychoactive mushrooms, in the event that it receives approval from the U.S. Food and Drug Administration.
-
January 20, 2026
CorMedix Investors Seek First OK Of Governance Reform Deal
Investors in CorMedix Inc. have told a New Jersey federal judge that company directors have agreed to implement several corporate governance reforms to resolve a consolidated shareholder derivative lawsuit accusing the executives of making misleading statements about delays in the regulatory approval of the company's lead drug candidate.
-
January 20, 2026
McCarter & English Knocks Down Biotech Malpractice Appeal
A New Jersey appellate court on Tuesday upheld the dismissal of a biotech company's malpractice and related claims against McCarter & English LLP, finding the biotech company was required to bring those allegations during the firm's earlier suit to recover more than $837,000 in unpaid legal fees.
-
January 20, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court wrapped up last week with a mix of deal litigation, governance fights and disclosure battles, including a proposed settlement over a contested medical device sale, a merits dismissal tied to a $2 billion biotech exit and dueling lawsuits over Paramount Skydance's pursuit of Warner Bros. Discovery.
-
January 16, 2026
Law360 Names Practice Groups Of The Year
Law360 would like to congratulate the winners of its Practice Groups of the Year awards for 2025, which honor the attorney teams behind litigation wins and significant transaction work that resonated throughout the legal industry this past year.
-
January 16, 2026
DOJ Reports Historic $6.8B False Claims Act Haul In 2025
The U.S. Department of Justice secured more than $6.8 billion via settlements and judgments under the False Claims Act in the fiscal year that ended September 2025, the largest amount recovered in a single year in the history of the FCA, the DOJ said Friday.
-
January 16, 2026
PBMs Seek Exit From Philly's Suit Over Opioid Crisis
CVS Health Corp. and other pharmacy benefit managers asked a Pennsylvania federal judge to let them out of the city of Philadelphia's lawsuit claiming they contributed to the opioid epidemic in the city, arguing that the city waited too long to file its suit and lacked standing to sue the companies.
-
January 16, 2026
SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
Former executives of Spero Therapeutics will pay over $187,000 to settle the U.S. Securities and Exchange Commission's claims they downplayed the likelihood that the U.S. Food and Drug Administration would reject the biopharmaceutical company's new drug application in 2022, the commission said on Friday.
-
January 16, 2026
Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit
Biotech company Lifecore Biomedical Inc. has reached a $3.8 million deal with its investors to end their claims the company had weak controls over its financial reporting, impairing its ability to remain compliant with Nasdaq listing requirements and causing share declines.
-
January 16, 2026
6th Circ. Revives Biomed Co. Investor's Suit Over Stock Sale
The Sixth Circuit has ruled that a man who sold his stock in a biomedical research company just before being told the company planned to pursue private equity financing can bring his breach of contract and fiduciary duty claims, reversing a lower court's ruling granting summary judgment to the biomedical company.
-
January 16, 2026
NuVasive Loses Appeal Over Ex-Exec's Ties To Competitor
The Delaware Supreme Court on Friday affirmed the dismissal of NuVasive Inc.'s long-running lawsuit accusing a former top executive of breaching fiduciary duties and contractual obligations while planning to move to a rival spine-surgery company, ending nearly a decade of litigation over alleged conflicts and disloyal conduct.
-
January 16, 2026
Acadia Investors Get Initial OK For $179M Settlement
Acadia Healthcare Co. Inc. investors have received the first OK from a Tennessee federal judge for a $179 million settlement in a class action alleging the company misled them about the strength of its U.K. operations.
-
January 16, 2026
Pomerantz To Lead Biohaven Investors' FDA Approval Suit
Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge said Friday.
-
January 16, 2026
Taxation With Representation: Stibbe, A&O Shearman, Latham
In this week's Taxation With Representation, Keurig Dr Pepper Inc. plans to complete its deal to snap up coffee company JDE Peet's NV, Boston Scientific Corp. acquires medical device company Penumbra Inc., and fitness and wellness platform parent Playlist merges with fitness technology company EGYM.
-
January 16, 2026
J&J Largely Loses Bid To Toss Former Atty's NJ Bias Suit
A New Jersey federal judge largely shot down Johnson & Johnson's bid to scrap a former company data privacy attorney's racial and gender discrimination suit and rejected its bid to sanction her over the case.
-
January 16, 2026
Supreme Court Takes On Hikma's 'Skinny Label' Patent Case
The U.S. Supreme Court agreed Friday to hear Hikma Pharmaceuticals Inc.'s appeal of a decision reviving a patent case over its "skinny label" on a generic heart drug, after the Trump administration urged the court to take the case.
-
January 16, 2026
Bioness $110M Sale Suit Heads to $8.9M Deal
A Delaware Chancery Court class action challenging the $110 million sale of medical device maker Bioness Inc. to Bioventus Inc. is reaching a resolution through an $8.9 million proposed settlement, capping years of litigation over whether the deal was engineered to favor the company's controlling creditor at the expense of minority stockholders.
-
January 15, 2026
SEC Says Healthcare Exec Misspent $10.6M In Investor Funds
The U.S. Securities and Exchange Commission on Thursday accused a healthcare company CEO of misappropriating over $10 million from investors by falsely claiming the funds would be used to develop cancer screening and treatment technology when in fact they were spent on credit card debt, luxury vehicles and strip club visits.
-
January 15, 2026
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading
New York Attorney General Letitia James on Thursday sued the former CEO of healthcare contractor Emergent BioSolutions Inc., alleging insider trading amid troubles manufacturing a COVID-19 vaccine, while signing a $900,000 settlement with the company over its approval of an executive trading plan.
-
January 15, 2026
Trial 'No Longer Warranted' After Judge's Stelara Reversal
The fate of insurer CareFirst's suit accusing Johnson & Johnson of using a merger and patent fraud to anticompetitively protect immunosuppressive drug Stelara from competition is in doubt after a Virginia federal judge reversed course and nixed key claims he had previously teed up for trial.
Expert Analysis
-
How Calif. High Court Is Rethinking Forum Selection Clauses
Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.
-
AI Litigation Tools Can Enhance Case Assessment, Strategy
Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.
-
Attys Beware: Generative AI Can Also Hallucinate Metadata
In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.
-
Lessons From Fed. Circ. On Expert Testimony In Patent Cases
Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.
-
When Atty Ethics Violations Give Rise To Causes Of Action
Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.
-
What's New In FDA's Latest Cell And Gene Therapy Guidance
New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.
-
Trending At The PTAB: A Potential Barrier To Serial Challenges
New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.
-
What's Changing For Cos. In New Calif. Hazardous Waste Plan
While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.
-
Fed. Circ. In September: The Printed Matter Doctrine Expands
The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.
-
Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split
In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.
-
Series
Practicing Stoicism Makes Me A Better Lawyer
Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.
-
Broader Eligibility For AI-Related Patents May Be Coming
A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.
-
Series
The Biz Court Digest: Texas, One Year In
A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.
-
AI Product Safety Insights May Expand Foreseeability
Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.
-
Series
Law School's Missed Lessons: Educating Your Community
Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.